The global antibody drug conjugates market size was US$ 4,990.8 million in 2021. The global antibody drug conjugates s market size is forecast to reach US$ 33,150.3 million by 2030, growing at a CAGR of 26.7% during the forecast period from 2022 to 2030.

Antibody-drug Conjugates, also known as ADCs, are biopharmaceutical therapies that combine monoclonal antibodies specific to surface antigens found on specific tumor cells with highly effective anti-cancer medications joined via a chemical linker.

Factors Influencing Market Growth

Among the factors driving the global market include the rising incidence of cancer, the increasing geriatric population, changing in lifestyle patterns globally.
The strict government restrictions and a surge in the cost of procedures, and lack of funds may slow down the overall market growth.
The growing research activities on antibody therapies, preclinical research, more research on advanced drug discoveries, and rising research on oncology diseases, and the increasing collaboration between research institutes, Biotechnology, and Biopharmaceuticals companies are forecast to offer lucrative growth in the market during the forecast period.
Impact Analysis of COVID-19

The COVID-19 pandemic has had a negative impact on the global antibody drug conjugates market. Several governments imposed a lockdown in order to curb the spread of the deadly virus. As a result, hospitals and care services had to reduce and focus on the COVID-19 patients. The American Cancer Society data indicates there was a 52% reduction in the diagnosis of breast cancer in 2021, whereas a 25% of reduction in the diagnosis of pancreatic cancer was felt in March and April 2020. Due to the decline in the diagnosis of cancer incidences, the global market demand declined. In addition, cancer patients were at increased risk of developing severe difficulties following SARS-CoV-2 virus infection. Thus, the COVID-19 pandemic had a negative impact on the global market growth.

Regional Insights

North America held dominance in the market and accounted for the major revenue share in 2020. As a result of the rising awareness about current therapies, the existence of major players, a high majority of cancer patients, and effective R&D expenditure.

Europe is forecast to have lucrative growth in the market during the forecast period. Among the factors driving the market include growing incidences of cancer, a rising geriatric population, and increasing investments in research and development. The increased cancer incidence indicates the requirement to adopt novel therapies like antibody-drug conjugates that effectively decrease the burden. Thus, this factor is forecast to drive market growth in the region.

Leading Competitors

The leading prominent companies profiled in the global antibody drug conjugates market are:

Novartis AG
Takeda Pharmaceutical Company Limited
F. Hoffman-La Roche Limited
Pfizer, Incorporated
Seattle Genetics Incorporated
Genentech Inc.
Immunogen Inc
Progenics Pharmaceuticals Inc
Immunomedics, Inc.
Bayer Healthcare Pharmaceuticals.
Agensys, Inc.
Concortis Biotherapeutics
Celldex Therapeutics Inc.
Sanofi S.A.
Synthon Holding B.V.
Other Prominent Players
Scope of the Report

The global antibody drug conjugates market segmentation focuses on Product Type, Technology, Target Type, Application, End-Users, and Region.

Segmentation based on Product Type

Adcetris
Kadcyla
Other Product Type
Segmentation based on Technology

Cleavable Linker
Non-Cleavable Linker
Segmentation based on Target Type

CD30 Antibodies
HER2 Antibodies
Other Target Types
Segmentation based on Application

Blood Cancer
Breast Cancer
Ovary Cancer
Lung Cancer
Skin Cancer
Brain Tumor
Other Applications
Segmentation based on End-User

Hospitals and Speciality Cancer Centers
Other End Users
Segmentation based on Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America